A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
NCT ID: NCT05858749
Last Updated: 2023-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
494 participants
OBSERVATIONAL
2022-06-20
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study includes participants who:
* are 18 years old or above and have mRCC
* took medicines that use the bodies immunity to fight against cancer as their first choice of treatment
* took other medicines after taking the above first choice of treatment
This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include:
* the length of time between the start of a patient's treatment and the end of treatment
* the length of time between the start of treatment and death
* physician assessment of a patient's response to treatment
We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
NCT00515697
A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00106613
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
NCT05745142
Acarbose in Combination with Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
NCT05487859
Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
NCT01026337
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with mRCC
Patients with mRCC in the IMDC
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or over at the time of mRCC diagnosis
* Received IO combination treatment in 1L such as receiving ipilimumab + nivolumab or an axitinib-based regimen (ie, axitinib + pembrolizumab or axitinib + avelumab) as 1L
* Received subsequent treatments following 1L (e.g., 2L, 3L)
* Actively treated at an IMDC clinical center (to avoid incomplete data)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Headquarters
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A4061100
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.